Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Biomarkers Identification for Apatinib and Bevacizumab in the Second-line Therapy for Colorectal Cancer: A Randomised Controlled Trial

NCT03743428 is registered in ClinicalTrials.gov with Shenzhen People's Hospital as lead sponsor.

NCT NCT03743428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03743428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Biomarkers Identification for Apatinib and Bevacizumab in the Second-line Therapy for Colorectal Cancer: A Randomised Controlled Trial
Lead sponsor
Shenzhen People's Hospital
Phase
Not applicable
Overall status
Suspended
Start date
October 22, 2020
Completion date
December 31, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms